Key Takeaways
• Nuclivision, a Belgian medtech startup, raised €5M in funding led by LUMO Labs, with participation from Heran Partners and imec.istart future fund.
• The company’s AI platform, Nuclarity, enhances PET imaging by reducing scan time and radiation without compromising diagnostic accuracy.
• The funding will support regulatory approval and the commercial launch across Europe and the U.S. in 2025.
• The solution aims to improve accessibility, safety, and cost-efficiency in nuclear medicine imaging for conditions such as cancer and Alzheimer’s.
Belgian healthtech innovator Nuclivision has secured €5 million in a funding round designed to support the commercial rollout of its AI-based PET imaging platform, Nuclarity.
round was led by LUMO Labs, with additional investments from Heran Partners and the imec.istart future fund.
The company, founded in 2022 by Maarten Larmuseau, Tomas Brants, and Simon DeKeyser, is developing solutions that aim to reduce the health, cost, and environmental burdens of nuclear medical imaging.
Transforming PET Imaging with AI
PET (Positron Emission Tomography) is widely used in diagnosing conditions such as cancer and neurological disorders. However, PET imaging typically requires radioactive tracers and lengthy scan times, both of which can limit its accessibility and safety.
Nuclivision’s AI platform, Nuclarity, is engineered to:
• Reduce the amount of radiotracers needed for each scan
• Decrease scan times while maintaining diagnostic accuracy
• Lower healthcare costs and environmental impact associated with PET imaging
This approach is especially relevant for hospitals and clinics under operational strain and those seeking more sustainable imaging solutions.
Clinical and Regulatory Trajectory
Nuclarity is currently in the final stages of regulatory approval. The company is preparing to launch commercially across Europe in the coming months and plans to enter the U.S. market by late 2025.
The solution is designed to seamlessly integrate into existing imaging workflows, particularly in specialties like:
-
Oncology
-
Neurology
-
Theranostics (personalized diagnostic and therapeutic approaches)
Nuclivision is guided by a board of clinical advisors and medical imaging experts, ensuring the platform remains aligned with real-world healthcare demands.
Funding and Impact Strategy
Investor interest is driven not only by the product’s commercial potential but also by its alignment with sustainability and access goals in healthcare.
LUMO Labs, which specializes in mission-driven technologies, is providing more than capital—offering strategic guidance, operational frameworks, and access to a deep international network.
A New Standard in Nuclear Medicine?
Nuclivision’s innovation reflects a larger shift in the medtech sector—where AI and automation are increasingly used to optimize complex, resource-intensive medical procedures.
As imaging demand continues to surge globally, particularly for aging populations and chronic disease management, solutions like Nuclarity may become essential to future-ready healthcare systems.
If successfully deployed, Nuclarity could contribute to:
• Earlier and safer disease detection
• Improved operational efficiency for nuclear medicine departments
• Lowered environmental impact from reduced radioactive waste
With a strong clinical foundation and supportive investor ecosystem, Nuclivision is positioning itself at the forefront of AI-powered diagnostics, targeting not just technological innovation, but also accessibility, safety, and sustainability in medical imaging.
For more news and insights, visit AI News on our website.
